Literature DB >> 33151477

Prognostic factors in IgG4-related disease: a long-term monocentric Chinese cohort study.

Ji Zongfei1,2, Ma Lingying1,2, Zhang Lijuan1,2, Sun Ying1,2, Chen Rongyi1,2, Liu Dongmei1,2, Kong Xiufang1,2, Dai Xiaomin1,2, Ma Lili1,2, Chen Huiyong1,2, Jiang Lindi3,4.   

Abstract

OBJECTIVES: Patients with IgG4-related disease (IgG4-RD) suffer high relapse rates during long-term treatment, but factors that predict relapse outcomes are not well established. In the present study, we aimed to identify predictive factors for treatment resistance and disease relapse in a Chinese IgG4-RD cohort.
METHODS: This study enrolled 102 patients newly diagnosed with IgG4-RD. Disease prognosis was determined by evaluating disease activity and dosage of glucocorticoids. Predictive factors for refractory and relapsed disease were identified by univariate analysis and Cox regression.
RESULTS: Among the 102 patients, 78 cases received medical treatment with regular follow-up (21 [6-111] months). During the follow-up period, 55 (70.5%) patients sustained clinical remission, and 23 (29.5%) patients suffered refractory or relapsed disease. The relapse rate of the patients with IgG4-RD was significantly higher among patients who stopped taking medicine than among those who continued treatment with glucocorticoids (GC) + immunosuppressor (IM). Serum TNF-α ≥ 13 pg/mL, sIL-2R ≥ 1010 U/mL, total cholesterol < 3.55 mmol/L, low-density lipoprotein < 2.0 mmol/L, IgG ≥ 20.2 g/L, and drug withdrawal were predictive factors for refractory and relapsed IgG4-RD. Multivariate Cox regression revealed that both sIL-2R and TNF-α were independent risk factors for refractory and relapsed disease. The combination of GC and IM treatment was an independent protective factor against refractory and relapsed IgG4-RD.
CONCLUSIONS: High serum levels of sIL-2R and TNF-α may be informative risk factors for refractory and relapsed IgG4-RD. Our data suggest that a combination treatment of GC along with IM may be protective against refractory and relapsed IgG4-RD. Key Points • High sIL-2R and TNF-α levels are informative risk factors for refractory and relapsed IgG4-related disease. • Combination treatment of GC with IM protects against refractory and relapsed IgG4-related disease.

Entities:  

Keywords:  IgG4-related disease; Prognosis; Prognostic factors; Relapse; Treatment resistance

Mesh:

Substances:

Year:  2020        PMID: 33151477     DOI: 10.1007/s10067-020-05484-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  3 in total

Review 1.  The Immunobiology of Immunoglobulin G4 and Complement Activation Pathways in IgG4-Related Disease.

Authors:  Shigeyuki Kawa
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

2.  Immunoglobulin G4-related disease in Hong Kong: clinical features, treatment practices, and its association with multisystem disease.

Authors:  P H Li; K L Ko; C Tk Ho; L L Lau; R Ky Tsang; T T Cheung; W K Leung; C S Lau
Journal:  Hong Kong Med J       Date:  2017-09-01       Impact factor: 2.227

3.  Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis.

Authors:  D V Parums; D L Brown; M J Mitchinson
Journal:  Arch Pathol Lab Med       Date:  1990-04       Impact factor: 5.534

  3 in total
  3 in total

1.  Clinical and pathological predictors of relapse in IgG4-related disease.

Authors:  Ji Zongfei; Chen Lingli; Sun Ying; Ma Lingying; Zhang Lijuan; Liu Dongmei; Dai Xiaomin; Hou Yingyong; Chen Huiyong; Ma Lili; Jiang Lindi
Journal:  Arthritis Res Ther       Date:  2022-05-11       Impact factor: 5.606

2.  Clinical Characteristics of Patients With IgG4-Related Disease Complicated by Hypocomplementemia.

Authors:  Yuya Fujita; Shoichi Fukui; Masataka Umeda; Sosuke Tsuji; Naoki Iwamoto; Yoshikazu Nakashima; Yoshiro Horai; Takahisa Suzuki; Akitomo Okada; Toshiyuki Aramaki; Yukitaka Ueki; Akinari Mizokami; Tomoki Origuchi; Hiroshi Watanabe; Kiyoshi Migita; Atsushi Kawakami
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

3.  Advantages of an alternate-day glucocorticoid treatment strategy for the treatment of IgG4-related disease: A preliminary retrospective cohort study.

Authors:  Sho Fukui; Takehiro Nakai; Satoshi Kawaai; Yukihiko Ikeda; Masei Suda; Atsushi Nomura; Hiromichi Tamaki; Mitsumasa Kishimoto; Sachiko Ohde; Masato Okada
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.